Endologix LLC announced the completion of the 150th case in the JAGUAR Study. This randomized controlled trial is evaluating Endologix's ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair devices in the treatment of abdominal aortic aneurysms (AAA). The JAGUAR (ObJective Analysis to GaUge EVAR Outcomes Through Randomization) Study is a prospective, randomized, multi-center study, designed to enroll 450 patients at up to 60 sites.

Three hundred patients will be randomly assigned to the ALTO cohort, with 150 allocated to the comparator group. The study will follow-up patients through five years, with outcomes independently adjudicated. Featuring a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation of innovative therapies for AAA patients.

ALTO utilizes a low-profile delivery system and, unlike standard EVAR devices, features an exclusive Adaptive Sealing Technology that molds in-situ to the patient's specific aortic neck anatomy.